Navigation Links
MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
Date:1/31/2008

e new 600 mg arm. Results from the study are expected to be reported in the third calendar quarter 2008.

Jim DeMesa, M.D., President and CEO of MIGENIX added, "With results from this study expected in the third quarter 2008, we now have another near-term clinical milestone. Additional key clinical milestones include Omigard Phase III results for preventing catheter-related infections (CLIRS study) expected by our partner, Cadence Pharmaceuticals, in the second half of 2008 (enrollment to be completed in the second quarter) and Cutanea Life Sciences, our partner in the CLS001 rosecea product, planning to advance CLS001 to Phase III."

About Celgosivir (MX-3253)

Celgosivir, an oral inhibitor of alpha-glucosidase I, is currently the only anti-HCV drug in clinical development which acts on host-directed glycosylation. In preclinical studies, celgosivir has shown in vitro synergy with various interferons on the market or in development including Pegasys, PEG-Intron, Infergen, Alferon and IFN-omega (with or without ribavirin) and other drugs in development for the treatment of HCV (e.g. polymerase inhibitors) and therefore could have the potential to be included as part of many combination therapeutic approaches to improve efficacy in future anti-HCV therapies.

Results announced in April 2007 from a Phase II study demonstrated a clinically significant benefit when celgosivir was added to the standard of care in non-responder patients. Interim results from the first 10 patients in the current viral kinetics study who had completed 4-weeks of therapy were reported in December 2007. Detailed analysis of data from these two studies, and an extension protocol designed to provide expanded access to the non-responder patients, provided the rationale for increasing the dose of celgosivir from 400mg per day to 600mg per day in combination therapy as the next step for the optimization and advancement of celgosivir.

About HCV

HCV, the most co
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
2. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
3. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
5. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
6. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
7. Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
8. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
9. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
10. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
11. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... According to new market research report ... Integration, Deployment & Support), by Service Model (SaaS, ... Others (Hybrid & Community)) - Global Forecast to ... Cloud Professional Services Market into various sub-segments with ... also identifies the drivers and restraints for this ...
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... orders to $5.8 million and provides a good start to Q4.  ... North America and one in the Middle ... at record levels," said Peter Bruijns , President & CEO. ... of Q3 than they have been for any complete year since ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 2Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 3Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 4Cloud Professional Services Market by Public, Private, Hybrid & Community Expected to Reach $34.41 Billion by 2019 - New Report by MarketsandMarkets 5aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... BC, March 20 /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ... a secured, convertible debenture agreement to borrow $400,000. ... to fund expenses associated with the,preparation of delinquent ... remaining assets of the Company. The principal and,interest, ...
... January 7,2008, Signalife received a deficiency letter from ... advised that Signalife would need to,comply with the ... under AMEX Rules 1003(a)(iii). This notification was,triggered by ... than,$50 million, which previously exempted Signalife from meeting ...
... as Interim President, HOUSTON, March 20 Nova ... marketer of ASTM quality biodiesel, announced,today that it has ... its Interim President. Mr. Zeidman has been a Nova ... Managing Director of the law firm,Greenberg Traurig, LLP since ...
Cached Biology Technology:Chromos enters into loan and lending arrangements 2AMEX Notifies Signalife That It Has Accepted Signalife's Plan of Compliance 2Nova Biosource Fuels Expands Senior Executive Team 2Nova Biosource Fuels Expands Senior Executive Team 3
(Date:10/15/2014)... to an unexpected extent. The outbreak does not follow ... shows a new disease dynamic in regions, where it ... German National Academy of Sciences Leopoldina, acatech – the ... of the German Academies of Sciences and Humanities have ... In the statement the academies call for the following ...
(Date:10/15/2014)... 15, 2014   Neurotechnology , a provider ... availability of the VeriLook Surveillance 3.0 software ... real-time biometric face identification using live video streams ... The new version not only identifies faces in ... objects while they are moving through the video ...
(Date:10/14/2014)... sequenced the house fly genome for the first time, ... an insect that thrives in pathogen-rich dung piles and ... the journal Genome Biology , will increase understanding ... flies quickly adapt to resist insecticides, which could lead ... domestica) carry and transmit more than 100 human and ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3House fly genome reveals expanded immune system 2
... Solutions, a global life sciences technology solutions company ... to announce the latest release of ENLIGHTEN ... ENLIGHTEN system, which provides a proven, highly ... clinical trial management system (CTMS), has effectively supported ...
... University of Tennessee, Knoxville, researchers have found ... an estrogen-like compound in the environment which could ... adversely affect fish, plants and human health. Previously, ... these impacts. Theodore Henry, an adjunct ...
... is pleased to announce the recipients of the 2010 ... Advancement of Biotherapy. The 6 award winners were presented ... in Los Angeles; they are: David Armstrong, MD, DPM, ... MD, MPH; Kosta Mumcuoglu, PhD; and Aletha Tippett, MD, ...
Cached Biology News:MedNet Solutions Announces Significant Enhancements to ENLIGHTEN, Its Flagship EDC / eClinical Solution 2UT researchers link algae to harmful estrogen-like compound in water 2BTER Foundation announces winners of the William S. Baer Award 2BTER Foundation announces winners of the William S. Baer Award 3
A camera based compact unit for high speed scanning of 2D barcoded tubes in a cluster rack. This reader has been designed to read both 96 and 48 tube rack configurations and be compatible with common...
... The inductive drives of VARIOMAG Magnetic Stirrers ... motors, belts, or mechanical bearings, making VARIOMAG ... addition, the VARIOMAG inductive drive can be ... dust or microorganisms. This is why VARIOMAG ...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
...
Biology Products: